Related Experiment Video
Updated: Aug 21, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Genotype-Phenotype Correlations Identify Phenotypic Differences in Sarcomere Mutation-Positive Hypertrophic
Insights
This study reveals significant genotype-phenotype correlations in hypertrophic cardiomyopathy (HCM), showing distinct cardiac magnetic resonance (CMR) imaging differences based on sarcomeric gene variants. MYBPC3 variants are linked to greater hypertrophy but better outcomes compared to MYH7 variants.
Area of Science:
- Cardiology
- Genetics
- Medical Imaging
Background:
- Previous studies on genotype-phenotype correlations in hypertrophic cardiomyopathy (HCM) have yielded inconsistent results.
- Inconsistent findings may stem from small study sizes and varied phenotyping methods.
Purpose of the Study:
- To identify genotype-phenotype correlations in sarcomeric variant-positive HCM patients.
- Utilize cardiac magnetic resonance (CMR) imaging and adverse outcome data from the National Heart, Lung, and Blood Institute (NHLBI) HCM Registry.
Main Methods:
- Analyzed 915 sarcomeric variant-positive HCM patients from the NHLBI Registry.
- Compared CMR measures of left ventricular (LV) hypertrophy, fibrosis, and function across genotype subgroups.
- Meta-analyzed findings with prior studies from a systematic review.
Main Results:
- Patients with thick-filament gene variants showed greater LV hypertrophy (maxLVWT, LV mass) than thin-filament gene variants.
- MYBPC3 variant carriers had greater maxLVWT and lower LV ejection fraction than MYH7 variant carriers.
- MYBPC3 carriers exhibited a lower risk of adverse clinical outcomes compared to MYH7 carriers.
Conclusions:
- Identified significant phenotypic differences characterizing HCM genotype subgroups, resolving prior discrepancies.
- The rarity of multiple sarcomeric variants limits their contribution to phenotypic variation in the general HCM population.
Background:
Previous studies of genotype-phenotype correlations in hypertrophic cardiomyopathy (HCM) have presented inconsistent conclusions, potentially reflecting small studies and non-uniform phenotyping.
Objectives:
We aimed to identify genotype-phenotype correlations in sarcomeric variant-positive HCM cardiac magnetic resonance (CMR) imaging and adverse outcome data in the National Heart, Lung, and Blood Institute (NHLBI) HCM Registry.
Methods:
Of 2750 overall patients, 915 sarcomeric variant-positive ones were subgrouped by genotype. CMR measures of left ventricular (LV) hypertrophy, fibrosis and function, and adverse events, were compared. Findings were meta-analyzed with prior studies from systematic review.
Results:
Patients with pathogenic variants in thick-filament genes had greater hypertrophy than those in thin-filament genes - maximal LV wall thickness (maxLVWT) (21.7 ± 5.0 vs. 20.0 ± 4.4mm, P <0.01) and indexed LV mass (81.9 ± 26.0 vs. 71.7 ± 13.3g/m 2 , P <0.001). Of the former, MYBPC3 carriers had greater maxLVWT than MYH7 carriers (22.2 ± 5.2 vs. 20.9 ± 4.5mm, P <0.01) but lower LV ejection fraction (63.1 ± 8.4 vs. 65.3 ± 8.4%, P <0.001). Findings remained significant after covariate adjustment and meta-analysis. 23 (∼1%) patients had >1 disease-linked variants with only 3 (∼0.11%) carrying >1 pathogenic variants. MYBPC3 carriers had lower risk of a multiple event composite than MYH7 carriers.
Conclusions:
In the largest CMR-based study to date, we identified significant phenotypic differences that characterize disease-gene subgroups and resolved prior discrepancies through systematic review and meta-analysis. However, carriage of >1 sarcomeric variants did not contribute much to variation in phenotypic severity in the general HCM population due to its rarity.
Condensed Abstract:
Prior studies of genotype-phenotype correlations in hypertrophic cardiomyopathy have produced inconsistent findings. In the largest study to date with CMR imaging, we identified significant correlations between disease phenotypes and genotype subgroups of sarcomeric variant-positive patients from the NHLBI Hypertrophic Cardiomyopathy Registry. Patients with disease-linked MYBPC3 variants had greater hypertrophy and lower ejection fraction than those with MYH7 variants but also less incidence of clinical outcomes. Patients with multiple variants were strikingly rare (∼1% of all patients). Ultimately, we discovered phenotypic differences that characterize rare genotype subgroups and resolved prior discrepancies through systematic review and meta-analysis.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Genetic Lingo
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Cardiomyopathy IV: Restrictive Cardiomyopathy

